EUVIMEDEUVIMED entdecken
Crossref

Artificial Intelligence Applications in COVID-19-Associated Coagulopathy: Lessons Learned

Gerard Gurumurthy, Filip Kisiel, Lianna Reynolds, Jecko Thachil

Seminars in Thrombosis and Hemostasis · 23.03.2026

DOI: 10.1055/a-2832-1944 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 23.03.2026. Verfasst von Gerard Gurumurthy und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, United Kingdom.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractCoronavirus disease 2019 (COVID-19)-associated coagulopathy (CAC) is a thromboinflammatory syndrome marked by endothelial injury, micro- and macrovascular thrombosis, and, in a minority, late consumptive bleeding. D-dimer elevation was found to be one of the most consistent laboratory abnormalities and an established marker of severity. In this review, we explore how artificial intelligence methods were applied during the pandemic to predict thrombotic and mortality outcomes and to clarify mechanisms. Across studies, a consistent lesson was that D-dimer is most informative even when embedded within multivariable and time-aware models. Mechanistic machine learning (ML) analyses converged on an IL-6-centered immunothrombotic network, which associated cytokine signaling with complement activation. They highlighted how integrated proteomic and coagulation phenotyping can identify potentially actionable pathways. ML also quantified residual thrombotic risk despite standard thromboprophylaxis, suggesting that a high-risk minority may be detectable for closer monitoring or trial enrolment. Most CAC models, however, remain retrospective with limited external validation. They are also vulnerable to D-dimer assay heterogeneity and may drift across variants and vaccination eras. Future progress will depend on prospectively validated models that can stratify treatable subgroups and guide risk-adapted anticoagulation and immunomodulatory strategies beyond acute COVID-19.

Autor:innen und Institutionen

  • The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, United Kingdom.
  • Addenbrooke's Hospital, Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Department of Chemical Engineering, The University of Manchester, Manchester, United Kingdom.
  • Department of Haematology, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

Zitieren

APA

Gurumurthy, G., Kisiel, F., Reynolds, L., & Thachil, J. (2026). Artificial Intelligence Applications in COVID-19-Associated Coagulopathy: Lessons Learned. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/a-2832-1944

Vancouver

Gurumurthy G, Kisiel F, Reynolds L, Thachil J. Artificial Intelligence Applications in COVID-19-Associated Coagulopathy: Lessons Learned. Seminars in Thrombosis and Hemostasis. 2026. doi:10.1055/a-2832-1944

BibTeX
@article{Gurumurthy2026,
  author = {Gurumurthy, Gerard and Kisiel, Filip and Reynolds, Lianna and Thachil, Jecko},
  title = {Artificial Intelligence Applications in COVID-19-Associated Coagulopathy: Lessons Learned},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2026},
  doi = {10.1055/a-2832-1944}
}
Kostenlos starten →